|Bid||87.39 x 1000|
|Ask||87.43 x 800|
|Day's Range||86.83 - 88.28|
|52 Week Range||57.00 - 89.30|
|Beta (3Y Monthly)||1.01|
|PE Ratio (TTM)||74.78|
|Earnings Date||Jul 29, 2019 - Aug 2, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||87.67|
Joining Yahoo Finance's Jen Rogers and Myles Udland is Jared Blikre to break down the week's market action in the S&P 500, its 11 sectors (where tech is leading the year again), as well as the weekly winners in the Nasdaq 100 — all with the help of our new YFi Interactive touch screen.
Health-care reform is coming, UBS analysts say, and it could have severe consequences for health companies.
A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.
Merck (MRK) receives FDA approval for Keytruda's label expansion in small cell lung cancer indication, marking the drug's first approval in this indication.
"Merger Monday" finally lived up to its billing this week in Biotech Land. announced just before the opening bell Monday that it was acquiring oncology concern Array Biopharma Inc. Pfizer paid a buyout premium of more than 60% to purchase Array.
Cancer therapy stocks rallied after Pfizer made a deal to boost its oncology offerings. These industry players may also be takeover targets.
Incyte Corp NASDAQ/NGS:INCYView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for INCY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold INCY had net inflows of $2.58 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.
Bitcoin trading was active again Monday amid a solid gain for the Nasdaq. The tech-laden index was helped by strength in software and biotech stocks.
Incyte (INCY) today announces 24-week results from its randomized, double-blind, dose-ranging, vehicle-controlled, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inhibitor therapy, in adult patients (18 to 75 years of age) with vitiligo. The study met its primary endpoint, demonstrating that significantly more patients treated with ruxolitinib cream for 24 weeks achieved a ≥50 percent improvement from baseline in the facial vitiligo area severity index (F-VASI50) score compared to patients treated with a vehicle control (non-medicated cream).
Is Incyte Corporation (NASDAQ:INCY) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have […]
Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.
Pfizer's (PFE) study on JAK inhibitor Xeljanz XR demonstrates the efficacy of the medicine when used as a monotherapy without methotrexate.
Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Philadelphia’s fourth turn hosting the Biotechnology Innovation Organization’s annual international conference concluded Thursday. The BIO 2019 event featured a variety of panel discussions, keynote interviews, fireside chats and company presentations, covering a myriad of topics in the life sciences industry.
Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.
The best biotech companies to invest in tend to have a commonality: A strong streak of earnings growth.